{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:46:23Z","timestamp":1794667583485,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012781","name":"Merck & Co., Inc. | MSD K.K.","doi-asserted-by":"publisher","award":["\u2013"],"award-info":[{"award-number":["\u2013"]}],"id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012781","name":"Merck & Co., Inc. | MSD K.K.","doi-asserted-by":"publisher","award":["\u2013"],"award-info":[{"award-number":["\u2013"]}],"id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Perioperative treatment strategies for HER2-positive esophagogastric adenocarcinoma remain suboptimal. Here in the open-label, phase 2 IKF\/AIO PHERFLOT trial, we evaluated the safety and efficacy of adding pembrolizumab and trastuzumab to FLOT chemotherapy in patients with localized HER2-positive esophagogastric adenocarcinoma. The primary endpoints are the pathological complete response rate and the 2-year disease-free survival rate. Secondary endpoints include the R0 resection rate, feasibility and safety. Exploratory endpoints include clinical efficacy in molecularly defined subgroups. In this prespecified interim analysis, given the limited median follow-up period of 14.8 months, only one of the primary endpoints, the pathological complete response rate, and selected secondary endpoints, including the R0 resection rate, feasibility and safety, are reported here. Among 31 enrolled patients, 30 proceeded to R0 resection, and one patient declined surgery without disease progression. The combination regimen resulted in grade \u22653 treatment-related serious adverse events in 48.4% of patients (15 out of 31) aligning with established toxicity profiles of the respective agents and no treatment-related deaths. After four cycles of therapy, the pathological complete response rate was 48.4% (95% confidence interval 30.2\u201366.9; 15 out of 31) in the intention-to-treat population, and the subtotal regression rate (TRG1b according to Becker classification) was 19.4% (95% confidence interval 7.5\u201337.5; 6 out of 31), resulting in a major pathological response rate of 67.7% (95% confidence interval 48.6\u201383.3; 21 out of 31). Responses tended to be enriched in tumors with strong HER2 expression (immunohistochemistry 3+), high PD-L1 combined positive scores and lower T stage, but were also observed in substantial fractions of HER2 immunohistochemistry 2+\/ISH+, T3 or T4 and combined positive scores &lt;10 tumors. These findings support the feasibility and antitumor activity of perioperative chemoimmunotherapy targeting HER2 and PD-1 and warrant further validation in randomized trials. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05504720\" ext-link-type=\"uri\">NCT05504720<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-03979-y","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:01:35Z","timestamp":1760774495000},"page":"4197-4204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9768-0086","authenticated-orcid":false,"given":"Alexander","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eray","family":"Goekkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah-Eddin","family":"Al-Batran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Moosmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Ettrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Goetze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gruen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Homann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lorenzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf-Dieter","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Rempel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Siegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2632-4195","authenticated-orcid":false,"given":"Christian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4096-3309","authenticated-orcid":false,"given":"Benjamin","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Broering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5959-7153","authenticated-orcid":false,"given":"Mariana Santos","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pauligk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mascha","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4619-9433","authenticated-orcid":false,"given":"Joseph","family":"Tintelnot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"3979_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca. Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"Ca. Cancer J. Clin."},{"key":"3979_CR2","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran, S. E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet 393, 1948\u20131957 (2019).","journal-title":"Lancet"},{"key":"3979_CR3","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran, S. E. et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 17, 1697\u20131708 (2016).","journal-title":"Lancet Oncol."},{"key":"3979_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner, J. et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N. Engl. J. Med. 392, 323\u2013335 (2025).","journal-title":"N. Engl. J. Med."},{"key":"3979_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697 (2010).","journal-title":"Lancet"},{"key":"3979_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600, 727\u2013730 (2021).","journal-title":"Nature"},{"key":"3979_CR7","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian, Y. Y. et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 402, 2197\u20132208 (2023).","journal-title":"Lancet"},{"key":"3979_CR8","first-page":"1150","volume":"8","author":"A Stein","year":"2022","unstructured":"Stein, A. et al. Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial. JAMA Oncol. 8, 1150\u20131158 (2022).","journal-title":"JAMA Oncol."},{"key":"3979_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","volume":"42","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen, S. et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial. J. Clin. Oncol. 42, 410\u2013420 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3979_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian, Y. Y. et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N. Engl. J. Med. 393, 217\u2013230 (2025).","journal-title":"N. Engl. J. Med."},{"key":"3979_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 25, 212\u2013224 (2024).","journal-title":"Lancet Oncol."},{"key":"3979_CR12","doi-asserted-by":"publisher","first-page":"102045","DOI":"10.1016\/j.xcrm.2025.102045","volume":"6","author":"T Alcindor","year":"2025","unstructured":"Alcindor, T. et al. Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: the role of M2 macrophage landscape in predicting response. Cell Rep. Med. 6, 102045 (2025).","journal-title":"Cell Rep. Med."},{"key":"3979_CR13","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/ijc.33696","volume":"149","author":"RD Hofheinz","year":"2021","unstructured":"Hofheinz, R. D. et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int. J. Cancer 149, 1322\u20131331 (2021).","journal-title":"Int. J. Cancer"},{"key":"3979_CR14","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1200\/JCO.2020.38.15_suppl.4502","volume":"38","author":"RD Hofheinz","year":"2020","unstructured":"Hofheinz, R. D. et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO. J. Clin. Oncol. 38, 4502 (2020).","journal-title":"J. Clin. Oncol."},{"key":"3979_CR15","doi-asserted-by":"publisher","first-page":"LBA331","DOI":"10.1200\/JCO.2025.43.4_suppl.LBA331","volume":"43","author":"AD Wagner","year":"2025","unstructured":"Wagner, A. D. et al. EORTC-1203 GITC \u201cINNOVATION\u201d: integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer: overall survival results. J. Clin. Oncol. 43, LBA331 (2025).","journal-title":"J. Clin. Oncol."},{"key":"3979_CR16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2018.09.007","volume":"175","author":"S Su","year":"2018","unstructured":"Su, S. et al. Immune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophages. Cell 175, 442\u2013457.e23 (2018).","journal-title":"Cell"},{"key":"3979_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","volume":"430","author":"BKR Chaganty","year":"2018","unstructured":"Chaganty, B. K. R. et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN\u03b3 secretion. Cancer Lett. 430, 47\u201356 (2018).","journal-title":"Cancer Lett."},{"key":"3979_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2023-006678","volume":"11","author":"L Paschold","year":"2023","unstructured":"Paschold, L. et al. First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial. J. Immunother. Cancer 11, 1\u201310 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"3979_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1158\/2326-6066.CIR-24-0561","volume":"13","author":"J Tintelnot","year":"2025","unstructured":"Tintelnot, J. et al. Inflammatory stress determines the need for chemotherapy in patients with HER2-positive esophagogastric adenocarcinoma receiving targeted therapy and immunotherapy. Cancer Immunol. Res. 13, 200\u2013209 (2025).","journal-title":"Cancer Immunol. Res."},{"key":"3979_CR20","doi-asserted-by":"publisher","first-page":"1021859","DOI":"10.3389\/fonc.2022.1021859","volume":"12","author":"M Noori","year":"2022","unstructured":"Noori, M., Yousefi, A. M., Zali, M. R. & Bashash, D. Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: a systematic review and meta-analysis. Front. Oncol. 12, 1021859 (2022).","journal-title":"Front. Oncol."},{"key":"3979_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10120-021-01227-z","volume":"25","author":"CS Fuchs","year":"2022","unstructured":"Fuchs, C. S. et al. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer 25, 197\u2013206 (2022).","journal-title":"Gastric Cancer"},{"key":"3979_CR22","doi-asserted-by":"publisher","first-page":"x61","DOI":"10.1093\/annonc\/mdx660.013","volume":"28","author":"J Cheon","year":"2017","unstructured":"Cheon, J. et al. Outcomes and predictive markers of trastuzumab-containing 1st-line chemotherapy in patients with HER2-positive advanced gastric cancer. Ann. Oncol. 28, x61 (2017).","journal-title":"Ann. Oncol."},{"key":"3979_CR23","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat. Med. 30, 1933\u20131942 (2024).","journal-title":"Nat. Med."},{"key":"3979_CR24","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","volume":"392","author":"C Andrea","year":"2025","unstructured":"Andrea, C. et al. Nonoperative management of mismatch repair\u2013deficient tumors. N. Engl. J. Med. 392, 2297\u20132308 (2025).","journal-title":"N. Engl. J. Med."},{"key":"3979_CR25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S2468-1253(22)00439-3","volume":"8","author":"G Chen","year":"2023","unstructured":"Chen, G. et al. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol. Hepatol. 8, 422\u2013431 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"3979_CR26","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3979_CR27","doi-asserted-by":"publisher","unstructured":"Peng, Z. et al. Atezolizumab and trastuzumab plus chemotherapy for ERBB2-positive locally advanced resectable gastric cancer: a randomized clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0522 (2025).","DOI":"10.1001\/jamaoncol.2025.0522"},{"key":"3979_CR28","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/annonc\/mdt141","volume":"24","author":"S Lorenzen","year":"2013","unstructured":"Lorenzen, S. et al. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann. Oncol. 24, 2068\u20132073 (2013).","journal-title":"Ann. Oncol."},{"key":"3979_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-08768-7","volume":"21","author":"E Giommoni","year":"2021","unstructured":"Giommoni, E. et al. Results of the observational prospective RealFLOT study. BMC Cancer 21, 1\u201311 (2021).","journal-title":"BMC Cancer"},{"key":"3979_CR30","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2021.39.15_suppl.4050","volume":"39","author":"H Li","year":"2025","unstructured":"Li, H. et al. Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric\/gastroesophageal junction (GEJ) adenocarcinoma. J. Clin. Oncol. 39, 4050 (2025).","journal-title":"J. Clin. Oncol."},{"key":"3979_CR31","first-page":"1","volume":"3","author":"MJ Valkema","year":"2021","unstructured":"Valkema, M. J. et al. Optimization of detection of residual disease after neoadjuvant therapy in patients with esophageal cancer. Ann. Esophagus 3, 1\u201314 (2021).","journal-title":"Ann. Esophagus"},{"key":"3979_CR32","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2967\/jnumed.118.224196","volume":"60","author":"MJ Valkema","year":"2019","unstructured":"Valkema, M. J. et al. Accuracy of 18F-FDG PET\/CT in predicting residual disease after neoadjuvant chemoradiotherapy for esophageal cancer. J. Nucl. Med. 60, 1553\u20131559 (2019).","journal-title":"J. Nucl. Med."},{"key":"3979_CR33","doi-asserted-by":"publisher","first-page":"TPS4185","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4185","volume":"42","author":"J Hipp","year":"2024","unstructured":"Hipp, J., Bruns, C. J., Schmoor, C., Weis, J. & Hoeppner, J. Trial: surgery as needed versus surgery on principle in patients with postneoadjuvant clinical complete tumor response of esophageal cancer. J. Clin. Oncol. 42, TPS4185 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3979_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(25)00027-0","volume":"26","author":"BJ van der Wilk","year":"2025","unstructured":"van der Wilk, B. J. et al. Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial. Lancet Oncol. 26, 425\u2013436 (2025).","journal-title":"Lancet Oncol."},{"key":"3979_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/annonc\/mdw695","volume":"28","author":"SM Swain","year":"2017","unstructured":"Swain, S. M. et al. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann. Oncol. 28, 761\u2013768 (2017).","journal-title":"Ann. Oncol."},{"key":"3979_CR36","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41591-024-02895-x","volume":"30","author":"MF Thomas","year":"2024","unstructured":"Thomas, M. F. et al. Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis. Nat. Med. 30, 1349\u20131362 (2024).","journal-title":"Nat. Med."},{"key":"3979_CR37","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(25)00130-5","volume":"26","author":"A Zaanan","year":"2025","unstructured":"Zaanan, A. et al. TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 26, 732\u2013744 (2025).","journal-title":"Lancet Oncol."},{"key":"3979_CR38","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.22.00380","volume":"40","author":"R-D Hofheinz","year":"2022","unstructured":"Hofheinz, R.-D. et al. FLOT versus FLOT\/trastuzumab\/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group. J. Clin. Oncol. 40, 3750\u20133761 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3979_CR39","doi-asserted-by":"publisher","unstructured":"Shitara, K. et al. Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: final analysis of the randomized, phase III KEYNOTE-585 study. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO-25-00486 (2025).","DOI":"10.1200\/JCO-25-00486"},{"key":"3979_CR40","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO-24-02463","volume":"43","author":"H Kawakami","year":"2025","unstructured":"Kawakami, H. et al. Phase II study (NO LIMIT, WJOG13320G) of first-line nivolumab plus low-dose ipilimumab for microsatellite instability-high advanced gastric or esophagogastric junction cancer. J. Clin. Oncol. 43, 2184\u20132195 (2025).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03979-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03979-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03979-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T12:20:41Z","timestamp":1768393241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03979-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3979"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03979-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S. reported institutional research grants from MSD during the conduct of the study and outside the submitted work from BeOne, BMS, GBA-Innovationsfond, Deutsche Krebshilfe, Exelixis, Jazz, MerckKgA, MSD, Servier, Pierre Fabre, Takeda and institutional fees for advisory boards or lectures from Amgen, Astellas, AstraZeneca, BeOne, BMS, Daiichi Sankyo, Jazz, Merck, MSD, Roche, Sanofi, Servier, Taiho and Takeda. E.G. reported personal fees from BMS and MSD during the conduct of the study; and personal fees from Servier, Roche, and Sanofi outside the submitted work. T.J.E. reported grants from Servier, nonfinancial support from Ipsen, and personal fees from MSD, BMS, AstraZeneca, Roche, Eisai, Pierre Fabre, Merck Serono and Bayer outside the submitted work. S.-E.A.-B. reported grants from BMS, MSD, Sanofi, Ipsen, Roche Hospira, Lilly, Vifor Pharma, Hospira, AstraZeneca, Immutep and Eurozyto and personal fees from Lilly, AstraZeneca and BMS outside the submitted work. M.B. reported grants from MSD covering the translational studies in this trial during the conduct of the study. J.T. declared travel support from BeOne and research support from Takeda and Jazz outside of the current work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}